PL363907A1 - Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. - Google Patents

Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.

Info

Publication number
PL363907A1
PL363907A1 PL02363907A PL36390702A PL363907A1 PL 363907 A1 PL363907 A1 PL 363907A1 PL 02363907 A PL02363907 A PL 02363907A PL 36390702 A PL36390702 A PL 36390702A PL 363907 A1 PL363907 A1 PL 363907A1
Authority
PL
Poland
Prior art keywords
receptor antagonists
treating pain
pyridine derivatives
vanilloid receptor
fused pyridine
Prior art date
Application number
PL02363907A
Other languages
English (en)
Polish (pl)
Inventor
Andrew James Culshaw
Peter Gull
Allan Hallett
Hong-Yong Kim
Max Peter Seiler
Kaspar Zimmermann
Yugang Liu
Mahavir Prashad
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107505A external-priority patent/GB0107505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL363907A1 publication Critical patent/PL363907A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02363907A 2001-03-26 2002-03-25 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. PL363907A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0107505A GB0107505D0 (en) 2001-03-26 2001-03-26 Organic compounds
US33828101P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PL363907A1 true PL363907A1 (en) 2004-11-29

Family

ID=26245894

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363907A PL363907A1 (en) 2001-03-26 2002-03-25 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.

Country Status (17)

Country Link
US (1) US7915264B2 (enExample)
EP (1) EP1377576A2 (enExample)
JP (1) JP4205430B2 (enExample)
KR (1) KR20030083755A (enExample)
CN (1) CN1500089A (enExample)
BR (1) BR0208338A (enExample)
CA (1) CA2441599A1 (enExample)
CZ (1) CZ20032561A3 (enExample)
HU (1) HUP0303623A2 (enExample)
IL (1) IL157815A0 (enExample)
MX (1) MXPA03008754A (enExample)
NO (1) NO326546B1 (enExample)
PE (1) PE20021161A1 (enExample)
PL (1) PL363907A1 (enExample)
RU (1) RU2003130221A (enExample)
SK (1) SK11952003A3 (enExample)
WO (1) WO2002076946A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280229B2 (en) 2000-08-21 2006-12-07 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
JP2004506714A (ja) 2000-08-21 2004-03-04 パシフィック　コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
DE60332316D1 (de) 2002-02-01 2010-06-10 Euro Celtique Sa 2-piperazinpyridine für die schmerzbehandlung
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
CA2526361C (en) 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006007851A2 (en) 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
DE102004039373A1 (de) 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
GB0506147D0 (en) * 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
JP2009536608A (ja) * 2005-05-11 2009-10-15 メルク シャープ エンド ドーム リミテッド バニロイド−１受容体（ｖｒ１）の機能を調節する２，３−置換縮合二環式ピリミジン４−（３ｈ）−オン
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2007045462A2 (de) * 2005-10-19 2007-04-26 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR100761222B1 (ko) * 2006-03-08 2007-10-04 성균관대학교산학협력단 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
MX2009002066A (es) 2006-08-23 2009-03-06 Neurogen Corp Analogos de 2-fenoxipirimidinona.
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
CL2008001112A1 (es) * 2007-04-20 2008-12-19 Novartis Ag Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.
JP5755879B2 (ja) * 2007-07-18 2015-07-29 ノバルティス アーゲー Ｖｒ−１アンタゴニストとｃｏｘ−２阻害剤との相乗的組合せ剤
JP5419894B2 (ja) * 2008-01-11 2014-02-19 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐｖ３モジュレーターとしての縮合ピリミジン誘導体
WO2009121036A2 (en) * 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives
NZ587771A (en) 2008-04-18 2011-05-27 Dae Woong Pharma Novel benzoxazine benzimidazole derivatives, pharmaceutical composition comprising same, and a use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CN104271579A (zh) 2012-05-03 2015-01-07 诺华股份有限公司 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶
EP3204347B1 (en) 2015-12-23 2024-10-23 Commonwealth Scientific and Industrial Research Organisation Enamine compounds for protecting against uv radiation
CN108863949B (zh) * 2018-07-09 2021-01-15 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
JPH09510695A (ja) 1994-01-03 1997-10-28 エイシア・ファーマシュウティカルズ，インコーポレイテッド ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
NO20034122D0 (no) 2003-09-16
JP2004528312A (ja) 2004-09-16
PE20021161A1 (es) 2003-02-21
CZ20032561A3 (cs) 2003-12-17
BR0208338A (pt) 2004-03-09
NO326546B1 (no) 2009-01-05
WO2002076946A3 (en) 2002-12-27
RU2003130221A (ru) 2005-04-10
CN1500089A (zh) 2004-05-26
JP4205430B2 (ja) 2009-01-07
KR20030083755A (ko) 2003-10-30
NO20034122L (no) 2003-09-16
US20040138454A1 (en) 2004-07-15
US7915264B2 (en) 2011-03-29
HUP0303623A2 (hu) 2004-03-01
WO2002076946A2 (en) 2002-10-03
CA2441599A1 (en) 2002-10-03
SK11952003A3 (sk) 2004-03-02
MXPA03008754A (es) 2004-02-18
EP1377576A2 (en) 2004-01-07
IL157815A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
PT1381363E (pt) Derivados de imidazo-(1,2-a)-piridina como antagonistas mglur5
MXPA03006250A (es) Compuestos heterociclicos terapeuticos.
IL159350A0 (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU8200501A (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
EP1248607A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
HUP0100934A3 (en) Use of fused pyridine derivatives for production pharmaceutical compositions for the treatment of depression, anxiety or psychopathy
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
MXPA03006408A (es) Antagonistas de receptores de histamina.
PT1317430E (pt) Derivados de (2-azabiciclo[2.2.1]hepta-7-il)-metanol como agonistas do receptor nocotinico de acetilcolina
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
MXPA03009930A (es) Antagonistas del receptor del factor liberador de corticotropina.
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA200102367B (en) New heterocyclic compounds for therapeutic use.
SI1333833T1 (sl) Nova spojina trisubstituiran-8H-pirido(2,3-d)pirimidin-7-on za zdravljenje bolezni, posredovanih s CSBP/p38-kinazo

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)